Qual é o preço para EQRx, Inc. (EQRX)

O preço para EQRx, Inc. (EQRX) é $2.34

Qual é a capitalização de mercado para EQRx, Inc. (EQRX)

A capitalização de mercado para EQRx, Inc. (EQRX) é $728.90M

EQRx, Inc. (EQRX) Margem Operacional

EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.

Ano	Margem Operacional	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Margem Operacional

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Margem Operacional	Diferença na Margem Operacional	País
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
CSL Limited CSL.AX	25.72%	-	AU
Moderna, Inc. MRNA.US	-149.01%	-	US
Lonza Group AG LONN.SW	0.00%	-	CH

Empresa

Margem Operacional

Diferença na Margem Operacional

País